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How this fits in: Comorbidities in COPD have been associated with higher increased mortality, 
hospital admission and polypharmacy but the exact prevalence of individual comorbidities varies in 
the literature. This is the largest cross-sectional study to date examining the extent and type of 38 
comorbidities associated with COPD. Extensive comorbidities in COPD were found compared to 
controls, with implications for advocating for integrated primary and secondary care as well as 
updated guidelines reflecting the complex comorbidities encompassing COPD.  
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Abstract 
Background 
COPD is common and a major cause of morbidity and mortality worldwide. Recent studies suggest 
that comorbidities in COPD increase the risk of hospitalisation, polypharmacy and mortality but their 
estimated prevalence varies widely in the literature.   
Aim 
To evaluate the prevalenceextent and type of 38 physical and mental health comorbidities 
associated with COPD compared to controls in a large nationally representative dataset. 
Design and Setting 
A Cross-sectional data analysis of 314 primary care practices in Scotland including 1,272,685 adults.  
Method 
Data on COPD and 31 other physical and 7 mental health comorbidities was extracted. The 
prevalence of individual and cumulative comorbidities was compared in people with COPD to 
controls, standardised by age, gender and socioeconomic deprivation. 
Results 
There were 51,928 patients with COPD (4.1%). 86.0% of people with COPD had at least one 
additional comorbidity, compared to 48.9% of controls. 22.3% of people with COPD had five or more 
conditions compared to 4.9% of controls (adjusted OR 2.63, 95%CI 2.56-2.70). 29 of the 31 physical 
conditions and 5 of the 7 mental health conditions were more prevalent in COPD patients than 
controls. The six most prevalent non respiratory comorbidities in the COPD group were hypertension 
(35.3%), painful conditions (24.5%), coronary heart disease (20.8%) , depression (19.1%), dyspepsia 
(13.7%) and diabetes mellitus (12.2%.) 
Conclusion 
People Patients with COPD have extensive physical and mental health comorbidities. Guidelines for 
COPD should reflect this complexity but optimal management will also require enhanced integration 
of primary and specialist health care.  
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Background  
Chronic Obstructive Pulmonary Disease (COPD) is a major global cause of morbidity and mortality 
and is expected to become the third leading cause of death worldwide by 2020.(1) It has a significant 
impact on quality of life, even in its early often undiagnosed stages (2) and is a leading cause of 
unscheduled hospital admission. Comorbid conditions are commonly associated with COPD and they 
further increase the risk of hospitalisation.(3, 4) Comorbidity in COPD has also been associated with 
higher levels of polypharmacy and higher mortality.(5, 6) Estimates of the prevalence of individual 
comorbidities associated with COPD vary substantially in the literature (7) and studies investigating 
COPD and comorbidities often only consider a single or small number of comorbidities. (8, 9)  Some 
studies have counted a larger number of comorbidities but have had limitations such as a lack of 
control group.(4, 10)  
There have been a small number of cross-sectional studies comparing comorbidities in COPD to 
controls, with variation in the number and type of comorbidities assessed. One Spanish study 
(11)included 6357 individuals with COPD from a total sample of 198,670  and compared the 
prevalence of 25 additional chronic diseases in those with COPD to controls; the most prevalent of 
which were hypertension, dyslipidaemia and obesity in the COPD group. Another cross sectional 
study was the largest to date including 15,018 individuals with COPD in a population of 341,329 (12) 
but the analysis was limited to determining and comparing the prevalence of eleven chronic 
conditions.  They found an increased prevalence of ischaemic heart disease, heart failure, 
depression, diabetes mellitus and lung cancer in COPD compared to controls. 
Mental health disorders are common in patients with COPD, although prevalence estimates vary 
substantially, for example from 10-42% for depression.(13) Hanania followed 2,118 patients with 
COPD and compared them to 578 controls in 12 countries and found a prevalence of depression of 
26% in COPD, 2-3 fold higher than the control group.(14) Comorbid depression or anxiety in COPD 
has been shown to increase health care utilisation for primary and secondary care and reduce 
treatment adherence.(13) Given that depression and anxiety are frequently under-diagnosed in 
COPD; their detection and treatment is therefore essential.(8, 13)   
The aim of this study was to determine the extent and number prevalence of physical and mental 
health comorbidities in people with COPD compared to controls in a large nationally representative 
dataset in Scotland. 
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Methods 
We obtained data from the Primary Care Clinical Informatics Unit at the University of Aberdeen for 
1,272,685 patients aged 25 and over who were alive and permanently registered with one of 314 
Scottish general practices on March 31, 2007.(16) Data on the presence of COPD, 31 chronic physical 
health conditions and 7 mental health conditions were extracted (listed in Appendix 1). This study 
was a secondary data analysis using the SPICE dataset from Barnett’s study. The comorbidities 
originally chosen were identified as important by NHS Scotland. (15) The dataset was representative 
of the  Scottish population in terms of age, sex and socioeconomic deprivation, with a more detailed 
explanation available elsewhere.(16)  We defined COPD using a set of read codes based on 
definitions used by NHS Scotland Information Services. There was no measure of severity of COPD in 
the data analysis. 
‘Controls’ were defined as all patients from the 1,272,685 group who did not have COPD.  To control 
for differences between the two populations in age, gender and deprivation levels we adopted a 
similar approach to that undertaken in previous papers(17)and generated standardised prevalence 
rates by age groups (25 to 34 years; 35 to 44; 45 to 54; 55 to 64; 65 to 74; 75 to 84 and 85 and over), 
gender and deprivation decile using the direct method. These age-gender-deprivation standardised 
rates were then used to calculate odds ratio (ORs) and 95% confidence intervals (95% CI) for the 
adults with COPD compared to controls without, for the prevalence of 31 physical conditions and 
seven mental health conditions. Furthermore, the overall number of physical and mental health 
conditions was documented. 
Socioeconomic deprivation was measured using the Carstairs deprivation score divided into deciles 
from the most affluent to the most deprived.  The Carstairs score is based on postcode of residence 
and is widely used in healthcare research as a measure of socioeconomic status.(18)  We used t-tests 
to analyse differences between groups and one-way analysis of variance for differences across age 
groups and deprivation deciles. For all statistical analyses, a p-value less than 0·05 was considered 
statistically significant. All analyses were performed in Stata version 13. The NHS Grampian Research 
Ethics Service approved the anonymous use of this data for research purposes. 
 
  
5 
 
Results 
There were 51, 928 (4.1%) people with COPD from the total sample of 1,272,685 adults aged 25 and 
over. People with COPD were somewhat more likely to be women than those without (46.4% vs 
49.0%), were older (mean age 65.1 years vs 50.6 years for controls, p<0.001), and were more likely 
to live in areas of high social deprivation (24% resident in the most deprived quintile vs 17.1% of 
controls) (Table 1).  
Overall Comorbidity 
Table 2 shows that only 14% of people with COPD did not have any additional conditions compared 
to 48.9% of people without COPD (standardised OR 0.16, 95% CI 0.15-0.17). The COPD group after 
adjusting for age, gender, and deprivation standardisation were significantly more likely than 
controls to have one or more additional conditions with differences increasing with each additional 
condition. The largest difference was for 5 or more comorbidities, found in 22.3% of the COPD group 
compared to just 4.9% for those without COPD (standardised OR 2.63, 95% CI 2.56-2.70).  
Compared to controls, individuals with COPD were significantly less likely to have no additional 
physical condition (COPD 17.5% vs. controls 54.7%; standardised OR 0.42 95% CI 0.41-0.43). Those 
with COPD were significantly more likely to have one or more non-COPD condition. The largest 
difference was for 5 or more physical conditions (COPD 14.8% vs. controls 2.9%; standardised OR 
2.51 95% CI 2.42-2.59).  
People with COPD were less likely to have no recorded mental health condition compared to 
controls (COPD 68.8% vs. controls 85.1%; standardised OR 0.50, 95% CI 0.49-0.51). Compared to 
controls, those with COPD were more likely to have one mental health condition (COPD 21.1% vs. 
controls 11.9%; standardised OR 1.73, 95% CI 1.69-1.77), and over twice as likely to have three or 
more mental health conditions (COPD 1.5% vs. controls 0.5% OR 2.51 95%CI 2.32-2.76). 
Comorbidity of Individual Conditions 
Table 3 demonstrates 29 out of the 31 physical conditions were significantly more prevalent in the 
COPD group compared to controls. The most prevalent conditions in the COPD group were 
hypertension (35.3%), painful conditions (24.5%),   asthma (21.4%) and coronary heart disease 
(20.8%).  The biggest differences between the COPD group and control group for individual 
conditions were for bronchiectasis (standardised OR 9.14, 95% CI 8.38-9.47) and asthma 
(standardised OR 5.07, 95% CI 4.96-5.18). Seven other physical conditions were more than twice as 
likely to be prevalent in those with COPD compared to controls; heart failure (OR 2.35), viral 
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hepatitis (OR 2.34), chronic sinusitis (OR 2.28), peripheral vascular disease (2.23), chronic liver 
disease (OR 2.15), psoriasis/ eczema (OR 2.03) and irritable bowel syndrome (OR 2.01). 
Table 4 shows that six of the seven mental health conditions were significantly more prevalent in the 
COPD group than controls. The COPD group had significantly higher prevalence of alcohol misuse, 
anxiety, depression, schizophrenia and dementia compared to the control group. After 
standardisation for age, sex and deprivation, the biggest differences were found for the prevalence 
of alcohol misuse (COPD 7.6% vs. controls 3.0%; standardised OR 2.48, 95% CI 2.40-2.57) and anxiety 
(COPD 11.2% vs. controls 3.9%; standardised OR 2.14, 95% CI 2.07-2.21). The most prevalent mental 
health condition in COPD was depression; 19.1% compared to 10.5% of controls (standardised OR 
1.77 95%CI 1.71-1.82).  
Discussion  
Summary of Key Findings 
The prevalence of COPD was 4.1% in this study, similar to the 3.4% found by a Canadian study (12, 
19) but higher than 1.4% in a study from England. (20)  
The aim was to We examined the prevalence of comorbidities in people with COPD, compared to 
those without, in the largest nationally representative primary care study to date. Individuals with 
COPD had excess physical and mental health comorbidities compared to those without, even after 
controlling for age, gender and deprivation. Thirty five of the thirty eight conditions examined were 
more common in people with COPD. The six most prevalent non- respiratory comorbidities in people 
with COPD were hypertension (35.3%), painful conditions (24.5%), coronary heart disease (CHD, 
20.8%), depression (19.1%), dyspepsia (13.7%) and diabetes mellitus (12.2%).  The study confirms 
that multiple comorbidity is extremely prevalent and this is known to be associated with an 
increased risk of hospitalisation, polypharmacy and mortality.(7, 21) 
Strengths and Limitations 
To the best of our knowledge, this is the largest study to date which has evaluated the prevalence of 
38 comorbidities in COPD in a nationally representative primary care sample. The data analysis was 
cross-sectional hence conclusions about causality cannot be made. Furthermore, the presence of a 
chronic illness may lead to increased diagnosis of other conditions due to closer monitoring.(22)  
Certain comorbidities were not specifically included in the analysis, such as lung cancer or 
pulmonary hypertension as this study involved a secondary data analysis and these conditions had 
been excluded from the primary data analysis. Furthermore, we acknowledge that certain conditions 
such as viral hepatitis were associated with smaller sample sizes (42 patients with COPD had viral 
hepatitis) compared to commoner conditions such as diabetes.  
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Smoking data was not included in the data analysis therefore we have not been able to make 
comparisons on levels of smoking in the COPD and control groups.  
 
Comparison with existing literature 
Within the COPD group, 86% had one or more comorbidities- similar to the prevalence ranging from 
76-82% found in three two recent studies.(4, 19, 23) An Italian cohort study of 569 people with 
COPD found that 81.2% had additional comorbidity and acute exacerbations of COPD were more 
common in those with a higher number of comorbidities.(4)    
The largest difference between the COPD group to those without was for bronchiectasis. A recent 
meta-analysis (24)which included fourteen observational studies found that comorbid bronchiectasis 
increased the risk of exacerbation and isolation of pathogenic microbes, such as pseudomonas, in 
the sputum. Furthermore, comorbid bronchiectasis was associated with an increased risk of severe 
airway obstruction and mortality.  
Asthma was commonly found in patients with COPD, which was expected for two reasons. First 
because some patients will have asthma-COPD overlap syndrome,(25) where there are chronic 
airway disease features overlapping both conditions. Typically, there is variable airflow obstruction 
which is not fully reversible.(25) Second, some people with COPD will be incorrectly coded as having 
asthma which may overstate the prevalence of asthma as a comorbidity. Chronic sinusitis was twice 
as common in the COPD group than the control group. Although a less commonly recognised 
phenomenon, sino-nasal involvement can impair quality of life and increase COPD 
exacerbations.(26)   
Previous studies have established that COPD is associated with hypertension and CHD (11, 21) which 
this study confirmed. CHD is frequently underdiagnosed in COPD which is important as the 
coexistence of CHD and COPD together worsens the prognosis compared to each individually.(27) 
Individuals with COPD were more likely to have heart failure, peripheral vascular disease, and 
cerebrovascular disease consistent with higher rates of hypertension, CHD, with smoking as a 
common risk factor.(5, 28, 29) Research by Rutten et al identified a prevalence of 20.5% of heart 
failure in COPD (compared to 6.4% in this study) when screened for the condition by using a number 
of diagnostic tests, highlighting the issue of underdiagnosis of heart failure in COPD.  (30) 
Comorbid dyspepsia in patients with COPD is inkeeping with a longitudinal study by Benson et al,(31) 
who noted a high prevalence of gastro-oesophageal reflux disease in patients with COPD, which was 
Formatted: Normal
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associated with an increased risk of exacerbation. Our study’s finding of increased prevalence of 
diabetes mellitus in COPD compared to controls (12.2%) was slightly lower than the prevalence 
documented in two cross-sectional studies of 18.7% (12) and 20%.(11) 
Our study found higher levels of alcohol misuse in patients with COPD which may in part explain the 
higher levels of chronic liver disease, but there were also strong associations with viral hepatitis. One 
small Japanese study found that chronic hepatitis C virus infection was associated with an 
accelerated decline in lung function in patients with COPD,(32) and hepatitis C was found to be more 
prevalent in people with COPD than the general population in Brazil (10.7% vs. 1.2-2%).(33). Further 
research is needed to evaluate whether there is a significant association between hepatitis C and 
COPD. Notably, our code ‘viral hepatitis’ did not differentiate between the hepatitis subtypes.  
A recent meta-analysis identified a statistically significant association between psoriasis and COPD, 
with a higher risk of developing COPD with more severe psoriasis, (34) confirming this study’s finding 
of increased risk of psoriasis in COPD compared to controls.  
We found that those with COPD were more likely to have one, and more than twice as likely to have 
two or more mental health conditions compared to controls. The biggest difference was for alcohol 
misuse, with the COPD group more than twice as likely to have been coded for this. There is a lack of 
studies investigating alcohol misuse prevalence in COPD. There is however evidence of high rates of 
smoking in those who misuse alcohol.(35) The prevalence of anxiety in the COPD group was 11% and 
of depression 19.1%, although both may be under-diagnosed.(13) In the literature (which includes 
heterogeneous often selected populations), the estimated prevalence of comorbid depression varies 
from 10-42%, and of anxiety 10-19%.(13) Comorbid mental health conditions have significant 
implications such as poor compliance with treatment, increased frequency of hospital admissions as 
well as prolonged inpatient stay.(8, 13) 
The exact mechanisms underpinning the diverse comorbidities associated with COPD are likely to be 
multifactorial and beyond the scope of this study. In short, some conditions may share common risk 
factors such as CHD and smoking.(3) However, evidence suggests that COPD is associated with 
chronic systemic inflammation, independent of smoking, which in turn may lead to insulin resistance 
(contributing to metabolic syndrome and diabetes), cachexia and a procoagulant state. (28, 36) 
COPD medication is also likely to exacerbate certain comorbidities; prednisolone could contribute to 
diabetes, osteoporosis and muscle dysfunction.(37)Further research is required to elucidate the 
exact mechanisms of the associated comorbidities.  
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Implications for Policy and Practice 
This study demonstrates the high prevalence of COPD and the fact that the presence of 
comorbidities is the rule rather than the exception. Our current healthcare model delivers 
fragmented care to patients with multiple comorbidities. We postulate that optimal management 
for these complex patients would involve the integration of specialist and primary care services in 
order to provide comprehensive and holistic health care. Primary care, unique in terms of offering 
expert generalist care, is best placed to provide this integrated approach.  
One recent Danish study (38) examining resource allocation in COPD found that multimorbidity in 
COPD significantly increased the annual fee for service health care expenditure. Although it is 
unsurprising for comorbidities to increase health care costs, this highlights evidence for the added 
economic burden as a result of comorbidities.  
Current guidelines for the COPD management do not take common comorbidities into account. The 
research behind the guidelines frequently excludes multimorbid patients, which influences the 
validity and generalisability of the treatments suggested for the majority of patients with COPD. 
There is a real need for guidelines and healthcare to reflect the complex reality of COPD 
complexities, encompassing detection of the common physical and mental health comorbidities and 
management of how best to deal with them in combination. This study plays a part in determining 
the prevalence of comorbidities in COPD which could contribute to the creation of these appropriate 
comprehensive guidelines. We speculate that by achieving this, we could potentially reduce the 
number of admissions, improve morbidity and mortality for patients with COPD, which in turn could 
have a significant economic and health-care impact. 
Conclusions 
The current study has illustrated that the majority of patients with COPD have complex physical and 
mental health comorbidity.   Firstly, we propose that the integration of primary and secondary care 
services would provide optimal holistic care for these patients.  Secondly, guidelines for COPD 
should be based on valid generalisable evidence and need to reflect the associated comorbidities in 
order to provide clear management strategies for clinicians. 
Formatted: Left, Line spacing:  Multiple 1.15 li
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Table 1 Age, Gender and Deprivation status, COPD Versus Controls 
Variable COPD  
Number (%) 
N=51,928 
No COPD 
Number (%) 
N=1,220,757 
Mean Age (sd) in Years 65.1 (14.5%) 50.6 (16.4%) 
Men 24,077 (46.4%) 598,005 (49.0%) 
Age group  
25-34 
35-44 
45-54 
55-64 
65-74 
75-84 
85 and above 
 
1,964 (3.8) 
3,388 (6.5) 
5,961 (11.5) 
11,077 (21.3) 
14,634 (28.2) 
11,551 (22.2) 
3,353  (6.5) 
 
227,432 (18.6) 
275,605 (22.6) 
247,833 (20.3) 
208,256 (17.1) 
140,646 (11.5) 
87,769 (7.2) 
33,216 (2.7)) 
Deprivation Deciles 
1 Least Deprived 
2 
3 
4 
5 
6 
7 
8 
9 
10 Most Deprived 
 
2,486 (4.8) 
3,364 (6.5) 
3,637 (7.0) 
5,659 (10.9) 
6,622 (12.8) 
6,637 (12.8) 
6,588 (12.7) 
4,487 (8.6) 
6,971 (13.4) 
5,477 (10.6) 
 
115,222 (9.4) 
 123,286 (10.1) 
 120,236 (9.9) 
 146,235 (12.0) 
 140,043 (11.5) 
 136,648 (11.2) 
 127,837 (10.5) 
 102,982 (8.4) 
 110,050 (9.0) 
 98,218 (8.1) 
 
 
All differences between the COPD and control group significant at p<0.001 
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Table 2 Prevalence and odds ratio for number and type of comorbidities (standardised by age, 
gender and deprivation score)  
 COPD 
Number (%) with 
conditions other 
than COPD 
N=51,928 
No COPD 
Number (%) with 
conditions other than 
COPD 
N=1,220,757 
Odds ratio (95% CI) 
(standardised by age, 
gender and deprivation) 
Total number of physical 
and mental health 
conditions 
None 
One 
Two 
Three  
Four 
Five or more 
 
 
 
7,264 (14.0) 
9,305 (17.9) 
9,194 (17.7) 
8,139 (15.7) 
6,460 (12.4) 
11,566 (22.3) 
 
 
 
597,363 (48.9) 
271,751 (22.3) 
150,858 (12.4) 
88,888 (8.8) 
51,961 (4.3) 
59,936 (4.9) 
 
 
 
0.16 (0.15-0.17) 
1.16 (1.14-1.18) 
1.38 (1.35-1.42) 
1.66 (1.61-1.70) 
1.95 (1.89-2.01) 
2.63 (2.56-2.70) 
Total number of physical 
conditions 
None 
One 
Two 
Three  
Four 
Five or more 
 
 
9,063 (17.5) 
10,971 (21.1) 
10,122 (19.5) 
8,253 (15.9) 
5,834 (11.2) 
7,685 (14.8) 
  
 
668,190 (54.7) 
266,951 (21.9) 
136,637 (11.2) 
73,986 (6.1) 
39,316 (3.2) 
35,677 (2.9) 
 
 
0.42 (0.41-0.43) 
1.23 (1.21-1.25) 
1.52 (1.48-1.56) 
1.78 (1.73-1.83) 
1.95 (1.88-2.03) 
2.51 (2.42-2.59) 
Total number of mental 
health conditions 
None 
One 
Two 
Three or more 
 
 
35,729 (68.8) 
11,324 (21.1) 
4,096  (7.9) 
779 (1.5) 
 
 
1,029,339 (85.1) 
145,819 (11.9) 
39,160 (3.2) 
6,439 (0.5) 
 
 
0.50 (0.49-0.51) 
1.73 (1.69-1.77) 
2.08 (2.00-2.15) 
2.51 (2.32-2.76) 
All differences between the COPD and control group significant at p<0.001 
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Table 3 Prevalence and odds ratios for individual physical conditions (standardised by age, gender and deprivation score). Conditions are ordered by size 
of odds ratio (largest to smallest). 
 
Condition COPD 
Number (%) 
N=51,928 
No COPD 
Number (%) 
N=1,220,757 
Odds ratio (95% CI) 
(standardised by age, 
gender and deprivation) 
Bronchiectasis 988 (1.9) 1,782 (0.2) 9.14 (8.38-9.47) 
Asthma 11,130 (21.4) 65,106 (5.3) 5.07 (4.96-5.18) 
Heart failure 3,344 (6.4) 15,526 (1.3) 2.35 (2.23-2.47)  
Viral hepatitis 42 (0.1) 1,096 (0.1) 2.34 (1.92-2.86)  
Chronic sinusitis 721 (1.4) 8,217 (0.7) 2.28 (2.13-2.45) 
Peripheral vascular disease (PVD) 3,494 (6.7) 19,437 (1.6) 2.23 (2.13-2.34) 
Cirrhosis/chronic liver disease/alcoholic liver disease 307 (0.6) 2,305 (0.2) 2.15 (1.87-2.48)  
Psoriasis or eczema 831 (1.6) 8,836 (0.7) 2.03 (1.88-2.18) 
Irritable bowel syndrome 3,316 (6.4) 47,141 (3.9) 2.01 (1.94-2.08)  
Painful condition 12,697 (24.5) 112,370 (9.2) 1.99 (1.94-2.04) 
Inflammatory arthritis and related conditions including 
gout 5,821 (11.2) 51,461 (4.2) 1.86 (1.80-1.92) 
Coronary heart disease 10,811 (20.8) 70,645 (5.7) 1.78 (1.72-1.83) 
Dyspepsia 7,112 (13.7) 71,481 (5.9) 1.78 (1.73-1.83) 
Constipation 4,358 (8.4) 31,737 (2.6) 1.66 (1.59-1.73) 
Diverticular disease 4,273 (8.3) 29,527 (2.4) 1.63 (1.56-1.71) 
Hearing loss 4,868  (9.4) 47,104 (3.9) 1.61 (1.55-1.67) 
Migraine 499 (1.0) 8,508 (0.7) 1.57 (1.44-1.71)  
Atrial fibrillation 3,065 (5.9) 20,894 (1.7) 1.53 (1.45-1.62)  
Stroke or transient ischaemic attack 4,307 (8.3) 32,167 (2.6) 1.50 (1.43-1.57)  
Epilepsy 663 (1.3) 10,886 (0.9) 1.48 (1.37-1.62) 
13 
 
Visual impairment 884 (1.7) 7,164 (0.6) 1.48 (1.34-1.62) 
Prostate disease 1,736 (3.3) 13,484 (1.1) 1.45 (1.35-1.55)  
Diabetes 6,315 (12.2) 67,410 (5.5) 1.41 (1.37-1.46) 
Thyrotoxicosis/thyroid disorders inc hypothyroidism 5,185 (10.0) 65,999 (5.4) 1.34 (1.30-1.39) 
Chronic  kidney disease 3,842 (7.4) 29,694 (2.4) 1.33 (1.27-1.40)  
Any new cancer in the last five years 3,731 (7.2) 39,275 (3.2) 1.29 (1.23-1.35) 
Inflammatory bowel disease 596 (1.2) 8,812 (0.7) 1.28 (1.17-1.40)  
Glaucoma 1,498 (2.9) 14,387 (1.2) 1.20 (1.11-1.29) 
Hypertension 18,346 (35.3) 215,741 (17.7) 1.17 (1.14-1.20) 
Multiple sclerosis 120 (0.2) 3,706 (0.3) 1.03 (0.88-1.21) p=0.62 
Parkinson’s disease and Parkinsonism 232 (0.5) 2,507 (0.2) 0.93 (0.77-1.13) p=0.50 
All differences between the COPD and control group significant at p<0.001 except where stated 
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Table 4 Prevalence and odds ratios for Individual Mental Health Conditions (Standardised by Age, Gender and Deprivation score). Conditions are 
ordered by size of odds ratio (largest to smallest). 
Mental Health Condition 
COPD 
Number (%prevalence) 
N=51,928 
No COPD 
Number (%prevalence) 
N=1,220,757 
Odds ratio (95% CI) 
(standardised by age, 
gender and deprivation) 
Alcohol misuse 3,952 (7.6) 36,616 (3.0) 2.48 (2.40-2.57) 
Anxiety & other neurotic, stress related & 
somatoform disorders 5,797 (11.2) 48,318 (3.9) 2.14 (2.07-2.21) 
Anorexia or bulimia 272 (0.5) 4,526 (0.4) 1.86 (1.67-2.08) 
Depression 9,941 (19.1) 128,200 (10.5) 1.77 (1.71-1.82) 
Schizophrenia (and related non-organic 
psychosis) or bipolar disorder 752 (1.5) 11,391 (0.9) 1.66 (1.54-1.78) 
Dementia 1,078 (2.1) 10,602 (0.9) 1.09 (1.00-1.19) p=0.04 
Learning Disability 125 (0.2) 4,311 (0.4) 1.06 (0.92 to 1.22) p=0.40 
All differences between the COPD and control group at p<0.001 except where stated 
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